vs
Side-by-side financial comparison of EAST WEST BANCORP INC (EWBC) and Moderna (MRNA). Click either name above to swap in a different company.
Moderna is the larger business by last-quarter revenue ($1.0B vs $775.0M, roughly 1.3× EAST WEST BANCORP INC). EAST WEST BANCORP INC runs the higher net margin — 46.2% vs -19.7%, a 65.9% gap on every dollar of revenue. On growth, EAST WEST BANCORP INC posted the faster year-over-year revenue change (2.1% vs -45.4%). Over the past eight quarters, EAST WEST BANCORP INC's revenue compounded faster (18.4% CAGR vs -45.0%).
East West Bank is an American bank that is the primary subsidiary of East West Bancorp. It is the largest publicly traded bank headquartered in Southern California. The company has been ranked the #1 performing U.S. bank with more than $10 billion in assets by S&P Global Market Intelligence, and the top performing bank in its asset size by Bank Director for three straight years since 2023.
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
EWBC vs MRNA — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $775.0M | $1.0B |
| Net Profit | $358.0M | $-200.0M |
| Gross Margin | — | 79.6% |
| Operating Margin | — | -25.6% |
| Net Margin | 46.2% | -19.7% |
| Revenue YoY | 2.1% | -45.4% |
| Net Profit YoY | 0.4% | -1638.5% |
| EPS (diluted) | $2.57 | $-0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $775.0M | — | ||
| Q4 25 | $657.8M | — | ||
| Q3 25 | $677.5M | $1.0B | ||
| Q2 25 | $617.1M | — | ||
| Q1 25 | $600.2M | — | ||
| Q4 24 | $587.6M | $966.0M | ||
| Q3 24 | $572.7M | $1.9B | ||
| Q2 24 | $553.2M | — |
| Q1 26 | $358.0M | — | ||
| Q4 25 | $356.3M | — | ||
| Q3 25 | $368.4M | $-200.0M | ||
| Q2 25 | $310.3M | — | ||
| Q1 25 | $290.3M | — | ||
| Q4 24 | $293.1M | $-1.1B | ||
| Q3 24 | $299.2M | $13.0M | ||
| Q2 24 | $288.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 79.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | — | 72.4% | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 71.0% | — | ||
| Q3 25 | 68.6% | -25.6% | ||
| Q2 25 | 65.2% | — | ||
| Q1 25 | 65.2% | — | ||
| Q4 24 | 60.6% | -129.0% | ||
| Q3 24 | 68.0% | -3.8% | ||
| Q2 24 | 65.9% | — |
| Q1 26 | 46.2% | — | ||
| Q4 25 | 54.2% | — | ||
| Q3 25 | 54.4% | -19.7% | ||
| Q2 25 | 50.3% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | 49.9% | -115.9% | ||
| Q3 24 | 52.2% | 0.7% | ||
| Q2 24 | 52.1% | — |
| Q1 26 | $2.57 | — | ||
| Q4 25 | $2.55 | — | ||
| Q3 25 | $2.65 | $-0.51 | ||
| Q2 25 | $2.24 | — | ||
| Q1 25 | $2.08 | — | ||
| Q4 24 | $2.10 | $-2.91 | ||
| Q3 24 | $2.14 | $0.03 | ||
| Q2 24 | $2.06 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.0B | $9.3B |
| Total Assets | $82.9B | $12.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | — | ||
| Q3 25 | $4.7B | $1.1B | ||
| Q2 25 | $4.4B | — | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $5.3B | $1.9B | ||
| Q3 24 | $4.9B | $1.6B | ||
| Q2 24 | $4.4B | — |
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | — | ||
| Q3 25 | $35.7M | — | ||
| Q2 25 | $35.8M | — | ||
| Q1 25 | $35.9M | — | ||
| Q4 24 | $36.0M | — | ||
| Q3 24 | $36.1M | — | ||
| Q2 24 | $36.1M | — |
| Q1 26 | $9.0B | — | ||
| Q4 25 | $8.9B | — | ||
| Q3 25 | $8.6B | $9.3B | ||
| Q2 25 | $8.2B | — | ||
| Q1 25 | $7.9B | — | ||
| Q4 24 | $7.7B | $10.9B | ||
| Q3 24 | $7.7B | $11.9B | ||
| Q2 24 | $7.2B | — |
| Q1 26 | $82.9B | — | ||
| Q4 25 | $80.4B | — | ||
| Q3 25 | $79.7B | $12.1B | ||
| Q2 25 | $78.2B | — | ||
| Q1 25 | $76.2B | — | ||
| Q4 24 | $76.0B | $14.1B | ||
| Q3 24 | $74.5B | $15.8B | ||
| Q2 24 | $72.5B | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-847.0M |
| Free Cash FlowOCF − Capex | — | $-880.0M |
| FCF MarginFCF / Revenue | — | -86.6% |
| Capex IntensityCapex / Revenue | — | 3.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $713.4M | — | ||
| Q3 25 | $231.7M | $-847.0M | ||
| Q2 25 | $278.7M | — | ||
| Q1 25 | $277.9M | — | ||
| Q4 24 | $500.1M | $825.0M | ||
| Q3 24 | $386.1M | $-1.6B | ||
| Q2 24 | $259.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-880.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $303.0M | ||
| Q3 24 | — | $-1.7B | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -86.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 31.4% | ||
| Q3 24 | — | -92.2% | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 3.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 54.0% | ||
| Q3 24 | — | 8.1% | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.00× | — | ||
| Q3 25 | 0.63× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 1.71× | — | ||
| Q3 24 | 1.29× | -120.46× | ||
| Q2 24 | 0.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EWBC
Segment breakdown not available.
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
